<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the efficiency of a combination of <z:chebi fb="0" ids="45924">trimethoprim</z:chebi> and <z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi> in patients with spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3/<z:e sem="disease" ids="C0024408" disease_type="Disease or Syndrome" abbrv="MJD|SCA3">Machado-Joseph disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Placebo-controlled, double-blind crossover trial in 22 patients with genetically confirmed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Study phases of 6 months were separated by a washout period of 4 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Dosages were a combination of <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>, 160 mg, and <z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi>, 800 mg, twice daily for 2 weeks, followed by a combination of <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>, 80 mg, and <z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi>, 400 mg, twice daily for 5.5 months </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: Outpatient department of the Neurological Clinic, Ruhr-University, Bochum, Germany </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURES: <z:hpo ids='HP_0001251'>Ataxia</z:hpo> ranking scale, self-assessment score, static posturography, and results of motor performance testing </plain></SENT>
<SENT sid="6" pm="."><plain>Effects on the visual system were studied using the achromatic Vision Contrast Test System and the Farnsworth-Munsell 100-hue test for color discrimination </plain></SENT>
<SENT sid="7" pm="."><plain>Physical and mental health were documented using the Medical Outcomes Study 36-Item Short-Form Health Survey </plain></SENT>
<SENT sid="8" pm="."><plain>Subgroup analyses assessed the influence of age, sex, age at <z:hpo ids='HP_0003674'>onset</z:hpo>, duration of the disease, phenotype, and CAG repeat length on test performance </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Twenty of 22 patients completed the study </plain></SENT>
<SENT sid="10" pm="."><plain>Dropouts were due to a <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> (placebo phase) and an <z:e sem="disease" ids="C0038663" disease_type="Mental or Behavioral Dysfunction" abbrv="">attempted suicide</z:e> in a <z:e sem="disease" ids="C0233542" disease_type="Mental or Behavioral Dysfunction" abbrv="">family conflict</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="45924">Trimethoprim</z:chebi>-<z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi> therapy had no significant effect in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients in the short-term analysis (2 weeks) or in the long-term interval (6 months) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: In contrast to previous reports that studied smaller groups of patients, treatment with <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>-<z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi> did not improve the diverse and complex <z:hpo ids='HP_0100022'>movement disorders</z:hpo> caused by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain><z:chebi fb="0" ids="45924">Trimethoprim</z:chebi>-<z:chebi fb="0" ids="9332">sulfamethoxazole</z:chebi> had no effect on the visual system and cannot be recommended as a continuous treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MJD</z:e> patients </plain></SENT>
</text></document>